证券代码：300039 证券简称：上海凯宝 公告编号：2025-041 上海凯宝药业股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 上海凯宝药业股份有限公司（以下简称"公司"、"上海凯宝"）第六届董事 会第七次会议、2024 年年度股东大会审议通过了《关于使用闲置自有资金进行委托 理财额度的议案》，在保证日常经营运作资金需求、有效控制投资风险的情况下， 同意公司及子公司使用闲置自有资金购买理财产品额度不超过人民币 8 亿元，其年 累计发生额不超过人民币 60 亿元，购买理财产品的额度自股东大会审议通过之日起 12 个月内可滚动使用。同时，在上述额度范围内授权管理层具体实施委托理财事宜， 包括但不限于委托理财的形式、期限及金额等。公司独立董事、监事会均发表了同 意的意见。具体内容详见公司于 2025 年 4 月 16 日、2025 年 5 月 16 日在巨潮资讯 网披露的相关公告。 截至本公告日，公司根据经营情况在以上决议授权范围内，使用闲置自有资金 进行银行理财产品、国债逆回购等委托理财事项，现就具体内 ...

证券日报网讯上海凯宝（300039）9月30日在互动平台回答投资者提问时表示，新谊牌元满酒为全资子 公司新谊药业产品，在京东和部分线下超市有售。 ...

证券之星消息，9月22日，上海凯宝（300039）融资买入1029.62万元，融资偿还919.7万元，融资净买入 109.92万元，融资余额3.82亿元，近3个交易日已连续净买入累计1154.92万元，近20个交易日中有12个 交易日出现融资净买入。 | 交易日 | 融资净买入(元) | | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | --- | | 2025-09-22 | | 109.92万 | 3.82亿 | 6.82% | | 2025-09-19 | | 230.63万 | 3.81亿 | 6.77% | | 2025-09-18 | | 814.37万 | 3.79亿 | 6.63% | | 2025-09-17 | | 1052.45万 | 3.71亿 | 6.42% | | 2025-09-16 | | -221.13万 | 3.60亿 | 6.24% | 融券方面，当日融券卖出1100.0股，融券偿还1000.0股，融券净卖出100.0股，融券余量18.12万股，近20 个交易日中有11个交易日出现融券净卖出。 | 交易日 | 融券冷卖用(股) ...

Core Insights - Shanghai Kaibao's stock price increased by 0.16% on September 17, with a trading volume of 249 million yuan [1] - The company reported a financing net purchase of 10.52 million yuan on the same day, with a total financing and securities balance of 372 million yuan [1] - As of June 30, 2025, Shanghai Kaibao's revenue decreased by 27.08% year-on-year, while net profit fell by 14.20% [2] Financing and Securities - On September 17, Shanghai Kaibao had a financing buy amount of 34.43 million yuan, with a current financing balance of 371 million yuan, representing 5.62% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of financing activity [1] - The company had a securities lending balance of 1.0181 million yuan, with a lending volume of 16,160 shares, also above the 80th percentile of the past year [1] Shareholder and Dividend Information - As of June 30, 2025, the number of shareholders decreased by 3.91% to 52,500, while the average circulating shares per person increased by 4.06% to 17,463 shares [2] - Since its A-share listing, Shanghai Kaibao has distributed a total of 1.521 billion yuan in dividends, with 272 million yuan distributed over the last three years [2] - The top ten circulating shareholders include significant institutional investors, with changes in holdings noted for several ETFs [2]

Group 1 - The core viewpoint of the article highlights that Shanghai Kaibao's financial performance for the first half of 2025 shows a decline in both revenue and net profit compared to the previous year [1] - The total operating revenue for the first half of 2025 is 605 million yuan, a decrease of 27.08% year-on-year, while the net profit attributable to shareholders is 122 million yuan, down 14.2% [1] - In Q2 2025, the operating revenue is 204 million yuan, reflecting a significant decline of 42.31% year-on-year, and the net profit for the quarter is 37.66 million yuan, down 29.84% [1] Group 2 - The gross profit margin for the first half of 2025 is 81.11%, a slight decrease of 0.57% compared to the previous year, while the net profit margin has increased to 20.13%, up 17.6% year-on-year [1] - Total expenses (selling, administrative, and financial) amount to 293 million yuan, accounting for 48.52% of revenue, which is a decrease of 4.58% year-on-year [1] - The company's earnings per share (EPS) is 0.12 yuan, a decrease of 14.2% year-on-year, while the operating cash flow per share is 0.15 yuan, an increase of 21.92% [1] Group 3 - The company's return on invested capital (ROIC) for the previous year was 7.97%, indicating an average capital return, with a historical median ROIC of 8.42% over the past decade [3] - The net profit margin for the previous year was 25.45%, suggesting a high added value for the company's products or services [3] - The company's business model is primarily driven by marketing, necessitating a thorough examination of the underlying factors behind this drive [3]

Core Viewpoint - Shanghai Kaibao reported strong financial performance in the first half of 2025, with significant revenue and profit growth, alongside advancements in research and product development [1] Financial Performance - The company achieved operating revenue of 605 million yuan in the first half of 2025, with a net profit attributable to shareholders of 122 million yuan [1] - The net cash flow from operating activities was 160 million yuan, reflecting a year-on-year increase of 21.92% [1] Research and Development - In the first half of 2025, the company invested 54.41 million yuan in research and development [1] - The company obtained one invention patent, one utility model patent, and one design patent during the reporting period [1] Product Development - The company received drug registration certificates for its classic formulations, including "Guo Yi Jian Granules" and "Ling Gui Zhu Gan Decoction Granules" [1] - The "Tan Re Qing Capsules" received approval for a new indication for use in the treatment of mild symptoms related to COVID-19, such as fever, cough, and sore throat [1] - Subsidiary Xinyi Pharmaceutical obtained registration approval for "Doxofylline Tablets," further enhancing the company's product line and market competitiveness [1] Company Overview - Shanghai Kaibao is primarily engaged in the research, production, and sales of modern traditional Chinese medicine [1] - The company is recognized as a national high-tech industrialization demonstration project base for modern traditional Chinese medicine and is among the first batch of traditional Chinese medicine enterprises to pass the new GMP certification [1] - The company has established three main product lines: respiratory products represented by "Tan Re Qing Injection/Capsules," cardiovascular products represented by "Qi Shen Capsules," and digestive products represented by "Sulfapyridine Series" [1]

每经AI快讯，上海凯宝8月28日发布半年度业绩报告称，2025年上半年营业收入约6.05亿元，同比减少 27.08%；归属于上市公司股东的净利润约1.22亿元，同比减少14.2%；基本每股收益0.1166元，同比减 少14.2%。 每经头条（nbdtoutiao）——世界首例基因编辑猪肺成功移植人体 对话主要参与者：距离临床应用还有 多远？ （记者 王瀚黎） ...

智通财经APP讯，上海凯宝(300039.SZ)发布2025年半年度报告，该公司营业收入为6.05亿元，同比减少 27.08%。归属于上市公司股东的净利润为1.22亿元，同比减少14.20%。归属于上市公司股东的扣除非经 常性损益的净利润为1.17亿元，同比减少17.81%。基本每股收益为0.1166元。 ...

Core Viewpoint - Shanghai Kaibao (300039.SZ) reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved a revenue of 605 million yuan, representing a year-on-year decrease of 27.08% [1] - The net profit attributable to shareholders was 122 million yuan, down 14.20% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 117 million yuan, reflecting a year-on-year decline of 17.81% [1] - Basic earnings per share stood at 0.1166 yuan [1]

截止报告期末，募集资金的使用和结余情况具体如下： 单位：元 上海凯宝药业股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》及相关格式指引的规定，上海凯宝药业股份有限公司（以下简称"公司"或"本 公司"）董事会编制了 2025 年半年度募集资金存放与使用情况的专项报告。 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会以证监许可[2009]1387 号文核准，并经深圳证券交易 所同意，公司由主承销商东吴证券有限责任公司采用网下向配售对象询价配售与网上 向社会公众投资者定价发行相结合的方式，向社会公开发行人民币普通股（A 股）股票 2,740 万股，每股发行价 38.00 元，共募集资金总额为 104,120 万元，扣除承销费和保 荐费 5,726.60 万元后的募集资金为 98,393.4 万元，扣除其他发行费用 1,017.64 万元 后，募集资金净额 97,375.76 万元。 公司对募集资金采取了专户存储制度，上述募集资金已由主承销商东吴证券有限 责任公司于 2009 年 1 ...